Patients in the earliest stage of the disease saw little to no decline over four years
Notifications can be managed in browser preferences.
Next article
Patients in the earliest stage of the disease saw little to no decline over four years
I would like to be emailed about offers, events and updates from The Independent. Read our Privacy notice
An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study.
Some patients involved in trials for lecanemab even saw cognitive scores improve
Researchers hope findings could help delay symptoms by five or six years
There is currently no cure for the disease nor any definitive way to predict how quickly Alzheimer’s disease will progress, but…
Finding can lead to therapies that alleviate ‘worst consequences of old age’
Scientists and doctors remain divided on the targeted antibody drugs that slow down the early stages of Alzheimer’s
Researchers said the test could transform the way the disease is detected
